内容紹介
Efficacy and Safety of Lenvatinib for Unresectable Anaplastic Thyroid Cancer
Summary
The 208 trial showed that lenvatinib has a significant antitumor effect on unresectable anaplastic thyroid cancer(ATC). Herein, we present a retrospective review of data from 7 patients with unresectable ATC who received lenvatinib in our hospital between May 2015 and October 2016. Two patients were men and 5 were women. The median age was 78(range, 72-85)years, and 1 patient had Stage ⅣA disease, 1 had Stage ⅣB, and 5 had Stage ⅣC at diagnosis, respectively. Three patients experienced a partial response and 1 patient experienced stable disease. The response rate was 43%, and the disease control rate was 57%. The median progression-free survival(PFS)was 4.1(range, 1.1-12.2)months. Grade 3 and Grade 4 gastrointestinal hemorrhage were observed in 2 patients and Grade 3 anorexia was observed in 1 patient. Further clinical research seems to be needed to establish a treatment strategy involving lenvatinib for ATC.
要旨
レンバチニブは国内第Ⅱ相試験(208試験)において,切除不能甲状腺未分化癌(anaplastic thyroid cancer: ATC)に対して高い抗腫瘍効果が示されている。本稿では,2015年5月～2016年10月までに当院で切除不能ATCに対してレンバチニブの投与を受けた7例を対象に,その有効性と安全性について報告する。男女比は2: 5,年齢中央値は78(72～85)歳,診断時Stage ⅣA 1例,Stage ⅣB 1例,Stage ⅣCが5例だった。部分奏効(PR)3例,安定(SD)1例,ORR 43%,DCR 57%,PFS中央値は4.1(1.1～12.2)か月だった。Grade 3以上の有害事象は消化管出血2例,食欲不振が1例に認められた。また,致死的合併症である頸動脈・静脈出血を来す可能性がある瘻孔形成を3例に認めた。今後さらにデータを集積して,レンバチニブの長期成績を検討していく必要がある。
目次
Summary
The 208 trial showed that lenvatinib has a significant antitumor effect on unresectable anaplastic thyroid cancer(ATC). Herein, we present a retrospective review of data from 7 patients with unresectable ATC who received lenvatinib in our hospital between May 2015 and October 2016. Two patients were men and 5 were women. The median age was 78(range, 72-85)years, and 1 patient had Stage ⅣA disease, 1 had Stage ⅣB, and 5 had Stage ⅣC at diagnosis, respectively. Three patients experienced a partial response and 1 patient experienced stable disease. The response rate was 43%, and the disease control rate was 57%. The median progression-free survival(PFS)was 4.1(range, 1.1-12.2)months. Grade 3 and Grade 4 gastrointestinal hemorrhage were observed in 2 patients and Grade 3 anorexia was observed in 1 patient. Further clinical research seems to be needed to establish a treatment strategy involving lenvatinib for ATC.
要旨
レンバチニブは国内第Ⅱ相試験(208試験)において,切除不能甲状腺未分化癌(anaplastic thyroid cancer: ATC)に対して高い抗腫瘍効果が示されている。本稿では,2015年5月～2016年10月までに当院で切除不能ATCに対してレンバチニブの投与を受けた7例を対象に,その有効性と安全性について報告する。男女比は2: 5,年齢中央値は78(72～85)歳,診断時Stage ⅣA 1例,Stage ⅣB 1例,Stage ⅣCが5例だった。部分奏効(PR)3例,安定(SD)1例,ORR 43%,DCR 57%,PFS中央値は4.1(1.1～12.2)か月だった。Grade 3以上の有害事象は消化管出血2例,食欲不振が1例に認められた。また,致死的合併症である頸動脈・静脈出血を来す可能性がある瘻孔形成を3例に認めた。今後さらにデータを集積して,レンバチニブの長期成績を検討していく必要がある。